Your body produces IGF-1 naturally. It’s one of the most important growth factors in biology — driving cell growth, protein synthesis, and tissue development. But there’s a catch: the moment IGF-1 enters the bloodstream, binding proteins grab onto it. Six different IGF-binding proteins (IGFBPs) sequester most circulating IGF-1, limiting how much actually reaches target tissues and activates the IGF-1 receptor.
IGF-1 LR3 was engineered to dodge those binding proteins. Two modifications — a 13-amino-acid N-terminal extension and a single amino acid swap at position 3 — reduce IGFBP binding by over 95%. The result: a growth factor with dramatically increased bioavailability that stays active in tissues roughly 20 times longer than native IGF-1.
This compound is supplied exclusively for in vitro and preclinical research. It is not intended for human consumption, therapeutic application, or diagnostic use.
The Engineering: Two Changes, Massive Impact
Native IGF-1 is a 70-amino-acid peptide. IGF-1 LR3 (Long Arginine 3) makes two structural modifications:
- 13-amino acid N-terminal extension: Added before the native sequence, this extension sterically hinders IGFBP binding — the binding proteins can’t grip the molecule properly with this extra piece in the way.
- Glu³→Arg³ substitution: Glutamic acid at position 3 is replaced with arginine. This single charge-swap further disrupts the IGFBP binding interface. The IGFBPs rely on specific electrostatic interactions with this region, and switching a negative charge (Glu) to a positive one (Arg) breaks the lock.
The combined effect: IGF-1 LR3 retains full affinity for the IGF-1 receptor (so it activates the same pathways as native IGF-1) but is largely invisible to the binding proteins that would normally sequester it. More of the compound reaches target cells, and it stays active longer.
Why Binding Proteins Matter So Much
In normal physiology, IGFBPs serve an important regulatory function — they control how much IGF-1 is “free” to activate receptors. IGFBP-3 alone carries about 75% of circulating IGF-1. This regulation prevents uncontrolled growth factor signaling.
For researchers, this creates a practical problem: if you administer native IGF-1 to a cell culture or animal model, most of it gets bound up by IGFBPs before it can do anything. You’re studying binding protein kinetics as much as IGF-1 biology. IGF-1 LR3 removes that variable — virtually all of the administered compound is bioavailable and receptor-active.
Research Applications
Cell Culture: The Primary Use Case
IGF-1 LR3 is widely used as a cell culture supplement, particularly for mammalian cell lines that benefit from IGF-1 signaling. Its extended bioactivity means less frequent media supplementation and more consistent growth factor levels between media changes. It’s become a standard tool in:
- Stem cell culture and differentiation protocols
- Myoblast (muscle cell) proliferation studies
- Hybridoma and biomanufacturing cell line maintenance
- Neuronal culture and differentiation
Muscle Biology
The IGF-1 pathway is one of the primary drivers of skeletal muscle hypertrophy. IGF-1 receptor activation triggers the PI3K/Akt/mTOR signaling cascade — the master pathway for protein synthesis and cell growth. IGF-1 LR3’s enhanced bioavailability makes it a more potent activator of this pathway in research settings, and it’s been used extensively in studies of muscle development, satellite cell activation, and regeneration.
Metabolic Research
IGF-1 has insulin-like effects on glucose metabolism (hence the name — insulin-like growth factor). IGF-1 LR3 has been used to study these metabolic effects with greater precision, since the reduced IGFBP binding allows researchers to titrate the growth factor signal without the confounding variable of variable binding protein levels between experimental subjects.
IGF-1 LR3 vs Native IGF-1: Quick Comparison
- Receptor affinity: Equivalent — same IGF-1R activation
- IGFBP binding: IGF-1 LR3 ~95% reduced — major difference
- Bioavailability: IGF-1 LR3 dramatically higher due to less sequestration
- Half-life: IGF-1 LR3 ~20-30 hours vs native IGF-1 ~12-15 minutes
- Molecular weight: 9,111 Da (LR3) vs 7,649 Da (native)
Product Specifications
- Molecular Weight: 9,111 g/mol
- Length: 83 amino acids (13aa extension + 70aa IGF-1 with Arg³)
- CAS Number: 946870-92-4
- Physical Form: Sterile lyophilized white powder
- Purity: ≥99% (verified by HPLC)
- Solubility: Soluble in bacteriostatic water or dilute acetic acid
- Storage: -20°C lyophilized; 2-8°C reconstituted
Key References
- Francis GL, et al. Insulin-like growth factor 1 and analogs with reduced affinity for IGF-binding proteins. J Mol Endocrinol. 1992.
- Tomas FM, et al. Superior potency of IGF-I LR3 compared to IGF-I in experimental animals. Growth Horm IGF Res. 1993.
- Clemmons DR. Role of IGF binding proteins in controlling IGF actions. Mol Cell Endocrinol. 1998.
Browse IGF-1 LR3 1mg with verified COA from Janoshik Analytical. For related growth factor research, see Ipamorelin, CJC-1295 + Ipamorelin, and our Growth Hormone Research category.